In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT collected data and analyzed the effectiveness of this biosimilar product in the real-world setting in patients with age-related macular degeneration, diabetic macular edema, and retinal vein occlusion (RVO).
Retinal vein occlusion (RVO) is a common cause of vision loss, and it can be treated with anti—vascular endothelial growth factor therapies such as ranibizumab (Lucentis).
While no biosimilars of ranibizumab are yet approved in the highly regulated territories of the United States or the European Union, in India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic in 2015; the retrospective study RE-ENACT collected data and analyzed the effectiveness of this biosimilar product in the real-world setting in patients with age-related macular degeneration, diabetic macular edema, and RVO. In a newly published subset analysis of the 160 patients with RVO who were enrolled in RE-ENACT, researchers found that the biosimilar effectively improved visual acuity and disease outcomes in the real-world setting.
The patients, all 18 years or older, received at least 3 ranibizumab injections between January 2016 and August 2016 as part of their routine care for RVO. The primary endpoints of the study were mean change in best corrected visual acuity (BCVA), mean change in central macular thickness (CMT), and the proportion of patients showing intraretinal or subretinal fluid.
The researchers found the following:
“The current subgroup analysis of patients with RVO showed that intravitreal injection of Razumab…is effective in reducing macular thickness and improving visual acuity in the real-world setting,” conclude the authors.
Reference
Sharma S, Khan MA, Chaturvedi A. Real-life clinical effectiveness of Razumab (the world’s first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT Study. Ophthalmologica. 2018;26:1-8. doi: 10.1159/000488602.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.